[1]
Derosa G,Maffioli P, α-Glucosidase inhibitors and their use in clinical practice. Archives of medical science : AMS. 2012 Nov 9; [PubMed PMID: 23185202]
[2]
Zhang M,Feng R,Yang M,Qian C,Wang Z,Liu W,Ma J, Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ open diabetes research & care. 2019 [PubMed PMID: 31641523]
[3]
Kumar S,Narwal S,Kumar V,Prakash O, α-glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacognosy reviews. 2011 Jan [PubMed PMID: 22096315]
[4]
Min SH,Yoon JH,Hahn S,Cho YM, Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis. Journal of diabetes investigation. 2018 Jul [PubMed PMID: 28950431]
[5]
Gao X,Cai X,Yang W,Chen Y,Han X,Ji L, Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. Journal of diabetes investigation. 2018 Mar [PubMed PMID: 28685995]
[6]
Bell DS,O'Keefe JH,Jellinger P, Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2008 Jan-Feb [PubMed PMID: 18238751]
[7]
Kim MK,Suk JH,Kwon MJ,Chung HS,Yoon CS,Jun HJ,Ko JH,Kim TK,Lee SH,Oh MK,Rhee BD,Park JH, Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes research and clinical practice. 2011 Jun [PubMed PMID: 21376417]
[8]
Yang HK,Lee SH,Shin J,Choi YH,Ahn YB,Lee BW,Rhee EJ,Min KW,Yoon KH, Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes & metabolism journal. 2019 Jun [PubMed PMID: 30604599]
[9]
DiNicolantonio JJ,Bhutani J,O'Keefe JH, Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open heart. 2015 [PubMed PMID: 26512331]
[10]
Göke B,Fuder H,Wieckhorst G,Theiss U,Stridde E,Littke T,Kleist P,Arnold R,Lücker PW, Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995; [PubMed PMID: 8536820]
[12]
Reuser AJ,Wisselaar HA, An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. European journal of clinical investigation. 1994 Aug [PubMed PMID: 8001622]
[13]
Hedrington MS,Davis SN, Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert opinion on pharmacotherapy. 2019 Dec [PubMed PMID: 31593486]
[14]
Dash RP,Babu RJ,Srinivas NR, Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica; the fate of foreign compounds in biological systems. 2018 Jan [PubMed PMID: 28010166]
[15]
Cai X,Han X,Luo Y,Ji L, Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. PloS one. 2013 [PubMed PMID: 24236131]